

Web references [Posted as supplied by the author]

- w1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med* 2005;353(16):1659-72.
- w2. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med* 2005;353(16):1673-84.
- w3. Pisters KM, Le Chevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. *J Clin Oncol* 2005;23(14):3270-8.
- w4. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med* 2004;350(23):2343-51.
- w5. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. *The Cochrane Database of Systematic Reviews* 2006, Issue 1. Art. No.: CD002092. DOI: 10.1002/14651858.CD002092.pub2.
- w6. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med* 2002;346(4):235-42.
- w7. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. *Lancet* 2002;359(9324):2131-9.
- w8. Lung Cancer. The diagnosis and treatment of lung cancer. Clinical guideline 24, February 2005, National Institute for Clinical Excellence.
- w9. Guidance on the use of Taxanes for Breast Cancer: National Institute for Clinical Excellence Technology Appraisal Guidance No 30. London: NICE www.nice.org.uk; September 2001.
- w10. Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer): National Institute for Clinical Excellence Technology Appraisal Guidance No.23. London: NICE www.nice.org.uk; April 2001.
- w11. Guidance on the use of paclitaxel in the treatment of ovarian cancer: National Institute for Clinical Excellence Technology Appraisal Guidance No.55. London: NICE www.nice.org.uk; January 2003.
- w12. Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: National Institute for Clinical Excellence Technology Appraisal Guidance No.93. London: NICE www.nice.org.uk; August 2005.
- w13. Guidance on the use of trastuzumab for the treatment of advanced breast cancer: National Institute for Clinical Excellence Health Technology Appraisal No.34. London: NICE www.nice.org.uk; March 2002.
- w14. Guidance on the use of gemcitabine for the treatment of pancreatic cancer: National Institute for Clinical Excellence Technology Appraisal Guidance No.25. London: NICE www.nice.org.uk; May 2001.